A Phase 3 interventional study of Baricitinib and Placebo in Covid19, sponsored by Incepta Pharmaceuticals Ltd. Withdrawn at 1 site in Bangladesh. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by Incepta Pharmaceuticals Ltd · Phase 3, Interventional, and Treatment
The study was planned during COVID-19 outbreak to assess Baricitinib in Patients With Moderate and Severe COVID-19. The study could not be started due to many obstacle which was raised because of Pandemic. The study is no more relevant.
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing baricitinib in COVID-19 — 3 open to participants now, 4 under way, 3 of them phase 3. baricitinib · COVID-19.
Among the 20 studies testing baricitinib in COVID-19, this one is the 18th largest by enrollment, is one of 13 that started in 2020, is one of 9 in phase 3, and was the 16th registered.
7,994 studies on the registry are indexed under COVID-19; 467 are open to participants now.
Browse COVID-19 studies →3 of the 20 studies testing baricitinib in COVID-19 are open now, in 12 countries. Recruiting first, the newest first:
Wes Ely · Sites in United States
Ages 18+
University of Oxford · Sites in Belgium, Estonia, France and 13 more countries
Ages 0+
UMC Utrecht · Sites in United States, Australia, Belgium and 26 more countries
Ages 28 days+
By country, each count listing its studies:
baricitinib: first FDA approval 2018 (OLUMIANT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 8 · Phase 3 13 · Phase 4 1
First in 2016; this study’s year is marked. 13 started in 2020.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 184 across the 20 interventional studies. Of the 7 that completed or were terminated, 3 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 20 have an industry lead sponsor. The 10 most frequent:
Incepta Pharmaceuticals Ltd is the lead sponsor of 4 studies on the registry; none are open to participants now.
Incepta Pharmaceuticals Ltd has 1 study filed under COVID-19 — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 20 studies testing baricitinib in COVID-19, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is multicenter clinical trial to evaluate efficacy and safety of Baricitinib in treatment for COVID-19. This trial will compare Baricitinib, a drug recommended for Rheumatoid Arthritis, against standard of care, to assess its relative effectiveness against COVID-19. By enrolling patients in multiple centers, this trial aims to recruit more patients to evaluate whether this drug slow disease progression or improve survival. Currently no effective therapeutics treatment or vaccine is available in the world for this highly transmissible respiratory borne infection, Covid-19. A number of drug trials are ongoing to measure the efficacy of the drug against the virus. Bangladesh as a resource limited country with limitation to provided health care services to the huge number of Covid-19 patients who will need hospitalization will be benefited from this study. There is no physical, psychological, social, legal risk in this study. The trial therapeutic will be approved form the Directorate of drug Administration (DGDA), Bangladesh.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Continued SOC together with oral 4 mg Baricitinib from day 1 to day 14
Drug: Baricitinib
Continued SOC according as mentioned in operational definition in the protocol
Drug: Placebo
Continued standard of care (SOC) together with oral 4 mg Baricitinib tablet from day 1 to day 14
Also known as: Baricent
Continued standard of care (SOC) together with oral placebo tablet from day 1 to day 14
Also known as: Given Orally
Clinical status assessed by a 7-point ordinal scale on Day 14
The ordinal scale is an assessment of the clinical status at a given study day. Each day, the worst(ie, lowest ordinal) score from the previous day will be recorded, ie, on Day 3, the lowest ordinal score from Day 2 is obtained and recorded for Day 2. The scale is as follows: 1. Death 2. Hospitalized, on invasive mechanical ventilation or ECMO 3. Hospitalized, on non-invasive ventilation or high flow oxygen devices 4. Hospitalized, requiring low flow supplemental oxygen 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise) 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care (other than per protocol Baricitinib administration) 7. Not hospitalized
Time frame: Day 1 to Day 14
The proportion of participants with treatment emergent adverse events
Time frame: Day 1 to Day 28
Time to clinical improvement (days): clinical improvement is defined as a ≥ 2-point improvement in clinical status (7-point ordinal scale) from Day 1
Time frame: Day 1 to Day 28
Time to ≥ 1-point improvement (days) from baseline clinical status
Time frame: Day 1 to Day 28
Time to recovery: defined as an improvement in clinical status from a baseline score of 2 through 5 to a score of 6 or 7, or an improvement from a baseline score of 6 to a score of 7
Time frame: Day 1 to Day 28
Duration of oxygen therapy (days)
Time frame: Day 1 to Day 28
Proportion of patients with shift in oxygen support status from baseline
Time frame: Day 1 to Day 28
Duration of hospitalization (days)
Time frame: Day 1 to Day 28
Number of patients with all-cause mortality at Day 28
Time frame: Day 1 to Day 28
Start is estimated for Jul 2020; primary completion for Jul 2025, 60 months later.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: start Oct 2021 → Jul 2020, primary completion Apr 2022 → Jul 2025 and completion Sep 2022 → Apr 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
The study was planned during COVID-19 outbreak to assess Baricitinib in Patients With Moderate and Severe COVID-19. The study could not be started due to many obstacle which was raised because of Pandemic. The study is no more relevant.
The study was planned during COVID-19 outbreak to assess Baricitinib in Patients With Moderate and Severe COVID-19. The study could not be started due to many obstacle which was raised because of Pandemic. The study is no more relevant.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is withdrawn, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Baricitinib
Incepta Pharmaceuticals Ltd